OncoZenge Announces Read-out of Positive Stability Data for BupiZenge™
Stockholm, Sweden – April 4, 2024 – OncoZenge AB (publ), a leading pharmaceutical company developing BupiZenge™, an innovative, non-opioid based treatment for oral pain, announces today that ongoing stability studies for the revised formulation of BupiZenge™ show positive results.Stability studies of BupiZenge™ are ongoing in line with previous communication from the company. The data now obtained shows 3 months of positive results within the desired limits of the specification for the development of the latest formulation. This data complements earlier data and analyzes and confirms the